<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Summary of guideline recommendations for ER and PR testing by immunohistochemistry in breast cancer patients</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Summary of guideline recommendations for ER and PR testing by immunohistochemistry in breast cancer patients</h1>
<div class="graphic"><div class="figure"><div class="ttl">Summary of guideline recommendations for ER and PR testing by immunohistochemistry in breast cancer patients</div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="subtitle1_single" colspan="2">Optimal algorithm for ER/PR testing</td> </tr> <tr> <td class="subtitle2_left">Recommendation</td> <td class="subtitle2_left">Comments</td> </tr> <tr> <td>Positive for ER or PR if finding of ≥1% of tumor cell nuclei are immunoreactive.</td> <td rowspan="2">These definitions depend on laboratory documentation of the following: <ol> <li>Proof of initial testing validation using clinically validated antibody </li> <li>Ongoing internal quality assurance procedures </li> <li>Participation in external proficiency testing </li> <li>Biennial accreditation by valid accrediting agency </li> </ol> </td> </tr> <tr> <td>Negative for ER or PR if finding of &lt;1% of tumors cell nuclei are immunoreactive in the presence of evidence that the sample can express ER or PR (positive intrinsic controls are seen).</td> </tr> <tr> <td class="subtitle1_single" colspan="2">Optimal testing conditions</td> </tr> <tr> <td class="subtitle2_left">Recommendation</td> <td class="subtitle2_left">Comments</td> </tr> <tr> <td rowspan="2">Large, preferably multiple core biopsies of tumor are preferred for testing if they are representative of the tumor (grade and type) at resection.</td> <td>Specimen should be rejected and repeated on a separate sample if any of the following conditions exist: <ol> <li>External controls are not as expected (scores recorded daily show variation) </li> <li>Artifacts involve most of sample </li> </ol> </td> </tr> <tr> <td>Specimen may also be rejected and repeated on another sample if: <ol> <li>Slide has no staining of included normal epithelial elements and/or normal positive control on same slide </li> <li>Specimen decalcified using strong acids </li> <li>Specimen shows an ER-/PR+ phenotype (to rule out a false-negative ER assay or a false-positive PR assay) </li> <li>Sample has prolonged cold ischemia time or fixation duration &lt;6 hours or &gt;72 hours and is negative on testing in the absence of internal control elements </li> </ol> </td> </tr> <tr> <td rowspan="2">Interpretation follows guideline recommendation.</td> <td> <ul> <li>Positive ER or PR requires ≥1% of tumor cells are immunoreactive; both average intensity and extent of staining are reported </li> <li>Image analysis is a desirable method of quantifying percentage of tumor cells which are immunoreactive </li> <li>H Score, Allred Score or Quick Score may be provided </li> <li>Negative ER or PR requires &lt;1% of tumor cells with ER or PR staining </li> </ul> </td> </tr> <tr> <td>Interpreters have method to maintain consistency and competency documented regularly.</td> </tr> <tr> <td>Accession slip and report must include guideline-detailed elements.</td> <td> </td> </tr> <tr> <td class="subtitle1_single" colspan="2">Optimal tissue handling requirements</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Recommendation</td> </tr> <tr> <td colspan="2"> <p>Time from tissue acquisition to fixation should be as short as possible. Samples for ER and PR testing are fixed in 10% neutral buffered fomalin (NBF) for 6 to 72 hours. Samples should be sliced at 5 mm intervals after appropriate gross inspection and margins designation and placed in sufficient volume of NBF to allow adequate tissue penetration.</p> <p>If tumor comes from remote location, it should be bisected through the tumor on removal and sent to the laboratory immersed in a sufficient volume of NBF. Cold ischemia time, fixative type, and time the sample was placed in NBF must be recorded.</p> </td> </tr> <tr> <td colspan="2">Storage of slides for more than six weeks prior to analysis is not recommended.</td> </tr> <tr> <td colspan="2">Time tissue is removed from patient, time tissue is placed in fixative, duration of fixation and fixative type must be recorded and noted on accession slip or in report.</td> </tr> </tbody></table></div><div class="graphic_lgnd">Guidelines from a combined panel from the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP).</div><div class="graphic_footnotes">ER: estrogen receptor; NBF: neutral buffered formalin; PR: progesterone receptor.</div><div class="graphic_reference">Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28:2784.</div><div id="graphicVersion">Graphic 65263 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
